Stay updated with breaking news from Pharma Mar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharma Mar (OTCMKTS:PHMMF – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline […]
(PLX AI) - Pharma Mar says good performance of the oncology business led to recurring revenues (sales plus royalties), growing by 7% in the first three months of the year to EUR 46 million.• Q1 net income
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the first patient was enrolled in EMERGE-201, a Phase 2 clinical trial evaluating the...
Open-label basket trial will assess the safety and efficacy of Zepzelca in patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination
Pharma Mar (OTCMKTS:PHMMF – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline […]